三生製藥(01530.HK)或於刊發2019年業績後繼續回購股份
格隆匯3月9日丨三生製藥(01530.HK)公佈,公司已於2020年2月27日及2020年2月28日進行股份購回。由於在董事會會議前就股份購回設有一個月的禁售期,本公司並無且將不會於該期間進行任何進一步的股份購回,直至2019年業績的公告日期為止。
公司的財務狀況穩健。董事會謹此告知公司的股東及潛在投資者,其或於刊發2019年業績後繼續根據購回授權行使其權力適時於公開市場購回股份。
此外,經考慮公司及其股東的整體利益,公司已於2020年3月9日在香港高等法院原訟法庭發出傳訊令狀。如令狀所載,公司對翁先生提出的申索包括下列內容:1.聲明該函件並不等同於有效要約;概無可獲接納的有效要約;該函件指稱的任何要約未獲有效接納;公司與翁先生之間並無具約束力的合約。2.聲明公司與翁先生之間的任何合約已獲撤銷。3.基於翁先生的失實陳述而對翁先生提出的損害賠償。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.